Genomics MarketSize, Share & Industry Analysis, 2026-2034By Application & TechnologyBy Proteomics Tools (2-D Page; Yeast 2-Hybrid Studies)By DeliverablesBy End-useBy Application Area

Genomics encompasses the instruments, reagents, consumables and analytical services used to sequence, genotype and functionally characterize DNA and RNA, spanning platforms such as next-generation sequencing, PCR, microarrays and mass-spectrometry-based proteomics tools. Buyers include pharmaceutical and biotechnology developers using genomic data to guide drug discovery and biomarker-driven trials, clinical and hospital laboratories running diagnostic and screening tests, academic and government research institutes, and agricultural and forensic laboratories applying the same core technologies to non-clinical samples.

The global genomics market stood at USD 45 billion in 2025. A forecast-period rate of 12.5% takes it to USD 129.88 billion by 2034, and the study reports every year in between, passing USD 27.94 billion in 2020, USD 40.91 billion in 2024, USD 50.63 billion in 2026 and USD 81.09 billion in 2030.

On the deliverables axis, growth rates run from 9.58% for Instruments/Systems/Software up to 16.72% for Computational Services. Consumables & Reagents carries the volume: USD 15.3 billion and 34% of revenue in 2025, USD 41.56 billion and 32% in 2034. NGS-based Services, Biomarker Translation Services and Computational Services take share over the period; Consumables & Reagents, Instruments/Systems/Software, Core Genomics Services and Others give it up while still growing in absolute terms.

By application & technology, Real-Time PCR accounts for 16% of 2025 revenue at USD 7.2 billion, reaching USD 16.88 billion and 13% by 2034. Bisulfite Sequencing grows faster at 16.78% against 9.93%, moving from 5% of revenue to 7% by 2034. This axis divides the same revenue as the deliverables split rather than adding to it, so the two are read together rather than summed.

USD 18.9 billion of 2025 revenue is generated in North America, 42% of the global total and the largest regional share; it reaches USD 49.35 billion by 2034. Europe is next at 26% and USD 11.7 billion, and Middle East and Africa last at 4%. Asia Pacific and Latin America gain share across the period, so growth is not distributed evenly between regions.

The 2025 total is triangulated from published sources and category proxies rather than an independently sourced count. Segment, regional and country splits are estimated on the same basis, which bounds the precision of the figures above. Coverage runs to five regions, seven deliverables lines and five segmentation axes across a fifteen-year window.

• Revenue grows from USD 45 billion in 2025 to USD 129.88 billion in 2034, a compound annual rate of 12.5%, having reached USD 40.91 billion in 2024 from USD 27.94 billion in 2020.
• 34% of 2025 revenue sits in Consumables & Reagents (USD 15.3 billion) and it remains the largest deliverables line in 2034 at USD 41.56 billion and 32%.
• At 16.72%, Computational Services grows faster than any other deliverables line, moving from USD 2.25 billion and 5% of revenue in 2025 to USD 9.09 billion and 7% in 2034.
• Scenario range for 2034 runs from USD 110.4 billion in the bear case to USD 149.36 billion in the bull case, against a base-case USD 129.88 billion, the spread a plan built on this forecast has to absorb.
• The largest region is North America, generating USD 18.9 billion in 2025 (42% of the global total) and USD 49.35 billion by 2034, ahead of Europe at 26%.
• The United States accounts for 78% of North America in the base year, worth USD 14.74 billion in 2025 and reaching USD 37.51 billion by 2034, the worked country example carried through that region's chapters.
• Every line on all five segmentation axes and in each of the five regions carries its own revenue, share and growth rate for all fifteen years, 2020 through 2034, on a 2025 base.

Three things move over 2026-2034, and they are worth separating: the deliverables mix, the regional balance, and the 12.5% compounding underneath both.

None of them reverses the market's direction. Every line and every region grows in absolute terms across the period; what changes is which of them captures the revenue added.

Composition shifts on the deliverables axis. Computational Services grows at 16.72% across 2026-2034 against 9.58% for Instruments/Systems/Software, the widest spread on the deliverables axis. Over the forecast period that moves Computational Services from 5% of revenue to 7%, and Instruments/Systems/Software from 24% to 19%. The revenue figures behind that are USD 2.25 billion to USD 9.09 billion and USD 10.8 billion to USD 24.68 billion. Both expand; where a supplier sits on the axis still decides whether it tracks the market.

Asia Pacific and Latin America gain regional share. Asia Pacific moves from 24% of revenue in 2025 to 29% in 2034, worth USD 10.8 billion rising to USD 37.66 billion; Latin America moves from 4% of revenue in 2025 to 5% in 2034, worth USD 1.8 billion rising to USD 6.49 billion. Share moves off the others in turn: North America at 42% moving to 38%, Europe at 26% moving to 24%, Middle East and Africa at 4% moving to 4%, each still growing in revenue terms. Revenue added in this market is therefore concentrating geographically rather than spreading evenly, and a participant weighted toward a share-losing region grows more slowly than the market even while its own revenue climbs.

Growth compounds at 12.5% without a step change. Fifteen years of revenue run USD 27.94 billion in 2020, USD 40.91 billion in 2024, USD 45 billion in 2025, USD 50.63 billion in 2026, USD 81.09 billion in 2030 and USD 129.88 billion in 2034. No year breaks the trajectory, and the 12.5% forecast rate compares with 10% recorded over 2020-2025, a continuation rather than an inflection. That moves the planning question away from timing a turn and onto the deliverables and regional mixes, where the actual movement is.

Computational Services adds the most incremental growth

Separate the 12.5% into its parts and three show up: an already-large base compounding, the deliverables mix moving toward its faster lines, and regional growth landing unevenly.

What holds the forecast back

What the bull case turns on

Revenue is concentrated in Consumables & Reagents

USD 18.9 billion of 2025 revenue is generated in North America, 42% of the global genomics market with USD 49.35 billion projected for 2034. It is a dominant region on this axis, first by revenue throughout the period.

Share settles at 38% in 2034, and the region keeps growing in absolute terms while others expand faster, a change in relative weight, not a decline in demand.

Segment composition follows the global pattern: Consumables & Reagents largest at 34% of 2025 revenue, Computational Services fastest at 16.72%. North America is reported axis by axis and country by country in the full study.

78% of North America's base-year revenue comes from the United States; USD 14.74 billion, rising to USD 37.51 billion by 2034. At 78% of regional revenue in the base year it is not one market among several, the region's trajectory is largely this country's trajectory. Regional revenue of USD 18.9 billion in 2025 and USD 49.35 billion in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.

the United States buys along the same lines as the market globally; Consumables & Reagents first at 34% of 2025 revenue and 32% in 2034, Computational Services fastest at 16.72% on a share moving from 5% to 7%. Since 78% of North America's revenue is generated here, the regional numbers inherit this market's mix rather than smoothing it out. Per-deliverables revenue for the United States appears on its own in the full report.

In the United States, genomic testing and sequencing products intended for clinical use fall under the Food and Drug Administration's medical device framework, with in vitro diagnostic tests requiring premarket clearance or approval depending on risk classification, while laboratory-developed genomic tests performed within a single laboratory have historically been overseen through the Clinical Laboratory Improvement Amendments program administered by the Centers for Medicare and Medicaid Services. Research-use-only reagents, instruments, and software are exempt from clinical claims but must carry labelling restricting their use to research settings. Suppliers marketing diagnostic-grade genomic products must demonstrate analytical and clinical validity and comply with quality system regulations governing manufacturing and labelling.

Competition in the United States runs between the suppliers this study tracks: Agilent Technologies, Bio-Rad Laboratories, Inc., BGI Genomics, Color Genomics, Inc., Danaher Corporation, Eppendorf AG, Eurofins Scientific, F. Hoffmann-La Roche Ltd., GE Healthcare, Illumina, Inc., Myriad Genetics, Inc., Oxford Nanopore Technologies, Pacific Biosciences of California, Inc., QIAGEN N.V., Quest Diagnostics Incorporated, Thermo Fisher Scientific, Inc. and 23andMe, Inc.. The commercially relevant division is 34% of 2025 revenue in Consumables & Reagents, where the volume is, against 16.72% growth in Computational Services, where share moves. Country-level shares and positioning per company sit in the full report.

Canada is sized at USD 2.84 billion in 2025, rising to USD 6.91 billion by 2034; 6.31% of global revenue and 15% of North America. It is reported separately from the United States across every segmentation axis in the full report.

USD 11.7 billion of 2025 revenue is generated in Europe, 26% of the global genomics market with USD 31.17 billion projected for 2034. By revenue it sits second across the study, and the ranking does not change between 2025 and 2034.

Share settles at 24% in 2034, while nothing contracts here; other regions simply grow faster, which shows up as relative weight rather than as falling revenue.

The deliverables mix reported at global level applies here, with Consumables & Reagents the largest line at 34% of 2025 revenue and Computational Services the fastest-growing at 16.72%. The full report breaks Europe out along every axis and by country.

Germany is the largest market within Europe, generating USD 3.51 billion in 2025 and projected to reach USD 9.04 billion by 2034. It accounts for 30% of regional revenue in the base year, the largest single share without dominating the region outright. The region itself runs USD 11.7 billion to USD 31.17 billion over the same period, and this is the market carrying the country-level detail in the full report.

Composition here matches the global split: the largest line is Consumables & Reagents at 34% of 2025 revenue, easing to 32% by 2034, and the fastest is Computational Services at 16.72%, from 5% to 7%. With 30% of Europe concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. Per-deliverables revenue for Germany appears on its own in the full report.

Genomics products sold in Germany are governed by the EU In Vitro Diagnostic Regulation, which classifies genomic and genetic testing devices by risk and generally requires notified body conformity assessment before a CE mark can be affixed, alongside conformity with harmonised standards on quality management and performance evaluation. Human genetic testing carried out for medical purposes additionally falls under Germany's Genetic Diagnostics Act, which sets conditions on who may order and interpret such tests and mandates counselling in defined circumstances. Suppliers must maintain technical documentation, post-market surveillance, and traceability, and any diagnostic claim must be substantiated through documented clinical and analytical performance evidence.

In Germany the field is Agilent Technologies, Bio-Rad Laboratories, Inc., BGI Genomics, Color Genomics, Inc., Danaher Corporation, Eppendorf AG, Eurofins Scientific, F. Hoffmann-La Roche Ltd., GE Healthcare, Illumina, Inc., Myriad Genetics, Inc., Oxford Nanopore Technologies, Pacific Biosciences of California, Inc., QIAGEN N.V., Quest Diagnostics Incorporated, Thermo Fisher Scientific, Inc. and 23andMe, Inc.. Consumables & Reagents, at 34% of 2025 revenue, is where the volume sits, and Computational Services, growing at 16.72%, is where position changes hands over the forecast period.

Within Europe, the United Kingdom accounts for 24% of regional revenue and 6.24% of the global total, worth USD 2.81 billion in 2025 and USD 7.17 billion by 2034.

France is sized at USD 2.11 billion in 2025, rising to USD 5.3 billion by 2034; 4.69% of global revenue and 18% of Europe. It is reported separately from Germany across every segmentation axis in the full report.

24% of the global genomics market sits in Asia Pacific in 2025, worth USD 10.8 billion on the way to USD 37.66 billion by 2034. That makes it the third-largest region covered, in 2025 and again in 2034.

By 2034 the share has moved up to 29%, because it outgrows the market's 12.5%; the revenue added here is disproportionate to where the region started.

Consumables & Reagents leads here as it does globally, at 34% of 2025 revenue, and Computational Services again grows fastest at 16.72%. Revenue for Asia Pacific is broken out by every segmentation axis and by country in the full report.

USD 4.1 billion of Asia Pacific's 2025 revenue is generated in China, the region's largest market, reaching USD 15.06 billion by 2034. Its 38% of base-year regional revenue leads the region, though enough sits elsewhere that Asia Pacific is not a proxy for it. Set against USD 10.8 billion and USD 37.66 billion for the region, it is why this market rather than a smaller one is the one reported in full.

Demand in China follows the deliverables mix reported at global level: Consumables & Reagents is the largest line at 34% of 2025 revenue, moving to 32% by 2034, while Computational Services grows fastest at 16.72% and takes its share from 5% to 7%. Its 38% weight in Asia Pacific means those movements carry straight into the regional totals. The full report reports China by deliverables separately.

In China, genomic testing kits and sequencing-based diagnostic devices are regulated by the National Medical Products Administration, which classifies in vitro diagnostic products by risk and requires registration testing, clinical evaluation, and manufacturing licensing before market entry, together with labelling that matches the approved intended use. Separately, the collection, storage, export, and international collaborative use of human genetic material and associated data are governed under China's human genetic resources administration rules, overseen by the relevant national science and technology authority, which require approval or filing before such resources leave the country or are shared with foreign partners. Suppliers operating across both regimes must satisfy device registration and genetic-resource compliance independently.

In China the field is Agilent Technologies, Bio-Rad Laboratories, Inc., BGI Genomics, Color Genomics, Inc., Danaher Corporation, Eppendorf AG, Eurofins Scientific, F. Hoffmann-La Roche Ltd., GE Healthcare, Illumina, Inc., Myriad Genetics, Inc., Oxford Nanopore Technologies, Pacific Biosciences of California, Inc., QIAGEN N.V., Quest Diagnostics Incorporated, Thermo Fisher Scientific, Inc. and 23andMe, Inc.. Consumables & Reagents, at 34% of 2025 revenue, is where the volume sits, and Computational Services, growing at 16.72%, is where position changes hands over the forecast period.

Japan is sized at USD 2.59 billion in 2025, rising to USD 7.91 billion by 2034; 5.76% of global revenue and 24% of Asia Pacific. It is reported separately from China across every segmentation axis in the full report.

3.84% of global revenue is generated in India; USD 1.73 billion in 2025, reaching USD 7.53 billion in 2034, and 16% of Asia Pacific.

USD 1.8 billion of 2025 revenue is generated in Latin America, 4% of the global genomics market on the way to USD 6.49 billion by 2034. It is a marginal region on this axis, fourth by revenue throughout the period.

Its share rises to 5% over the forecast period, at a pace above the 12.5% global rate, which is what makes this region worth reading separately rather than scaling from the total.

Segment composition follows the global pattern: Consumables & Reagents largest at 34% of 2025 revenue, Computational Services fastest at 16.72%. The full report breaks Latin America out along every axis and by country.

USD 0.81 billion of Latin America's 2025 revenue is generated in Brazil, the region's largest market, reaching USD 2.86 billion by 2034. It accounts for 45% of regional revenue in the base year, the largest single share without dominating the region outright. Against regional totals of USD 1.8 billion in 2025 and USD 6.49 billion in 2034, it is the country the full report breaks out in detail.

Demand in Brazil follows the deliverables mix reported at global level: Consumables & Reagents is the largest line at 34% of 2025 revenue, moving to 32% by 2034, while Computational Services grows fastest at 16.72% and takes its share from 5% to 7%. With 45% of Latin America concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. The full report reports Brazil by deliverables separately.

In Brazil, genomic and genetic testing products intended for diagnostic use are regulated by ANVISA, the national health surveillance agency, which requires registration of in vitro diagnostic devices and kits, classification by risk, and adherence to good manufacturing practice and labelling requirements before commercialisation. Access to and use of Brazil's genetic heritage for research or product development is separately governed under the national biodiversity access framework, administered through the SisGen registration system, which requires prior authorisation and benefit-sharing arrangements where applicable. Where genomic products intersect with genetically modified organisms, oversight from the National Technical Biosafety Commission may also apply, adding a further layer of approval before use or release.

In Brazil the field is Agilent Technologies, Bio-Rad Laboratories, Inc., BGI Genomics, Color Genomics, Inc., Danaher Corporation, Eppendorf AG, Eurofins Scientific, F. Hoffmann-La Roche Ltd., GE Healthcare, Illumina, Inc., Myriad Genetics, Inc., Oxford Nanopore Technologies, Pacific Biosciences of California, Inc., QIAGEN N.V., Quest Diagnostics Incorporated, Thermo Fisher Scientific, Inc. and 23andMe, Inc.. Volume sits in Consumables & Reagents at 34% of 2025 revenue; movement sits in Computational Services at 16.72% growth.

Mexico is sized at USD 0.54 billion in 2025, rising to USD 1.95 billion by 2034; 1.2% of global revenue and 30% of Latin America. It is reported separately from Brazil across every segmentation axis in the full report.

USD 1.8 billion of 2025 revenue is generated in Middle East and Africa, 4% of the global genomics market with USD 5.2 billion projected for 2034. That makes it the fifth-largest region covered, in 2025 and again in 2034.

4% of global revenue sits here in 2034, below the 2025 level, a shift in share rather than in direction: revenue climbs every year while the market's centre of gravity moves elsewhere.

Consumables & Reagents leads here as it does globally, at 34% of 2025 revenue, and Computational Services again grows fastest at 16.72%. Per-axis and per-country detail for Middle East and Africa sits in the full report.

Saudi Arabia is the largest market within Middle East and Africa, generating USD 0.63 billion in 2025 and projected to reach USD 1.87 billion by 2034. Its 35% of base-year regional revenue leads the region, though enough sits elsewhere that Middle East and Africa is not a proxy for it. The region itself runs USD 1.8 billion to USD 5.2 billion over the same period, and this is the market carrying the country-level detail in the full report.

The deliverables pattern in Saudi Arabia is the global one: 34% of 2025 revenue in Consumables & Reagents, 32% by 2034, against 16.72% growth in Computational Services taking it from 5% to 7%. Its 35% weight in Middle East and Africa means those movements carry straight into the regional totals. Revenue by deliverables for Saudi Arabia is reported separately in the full report.

In Saudi Arabia, genomic testing kits and sequencing-related in vitro diagnostic devices fall under the authority of the Saudi Food and Drug Authority, which requires manufacturer and product registration through its medical device marketing authorisation system before a product may be sold, generally aligned with internationally recognised device classification and conformity assessment principles. Suppliers must demonstrate conformity with applicable quality management and safety standards, maintain appropriate technical documentation, and ensure labelling and intended-use claims match what has been authorised. Genetic and genomic research activities involving human samples may additionally require ethical approval from an accredited institutional review body before testing or data collection can proceed.

In Saudi Arabia the field is Agilent Technologies, Bio-Rad Laboratories, Inc., BGI Genomics, Color Genomics, Inc., Danaher Corporation, Eppendorf AG, Eurofins Scientific, F. Hoffmann-La Roche Ltd., GE Healthcare, Illumina, Inc., Myriad Genetics, Inc., Oxford Nanopore Technologies, Pacific Biosciences of California, Inc., QIAGEN N.V., Quest Diagnostics Incorporated, Thermo Fisher Scientific, Inc. and 23andMe, Inc.. The commercially relevant division is 34% of 2025 revenue in Consumables & Reagents, where the volume is, against 16.72% growth in Computational Services, where share moves.

1% of global revenue is generated in South Africa; USD 0.45 billion in 2025, reaching USD 1.25 billion in 2034, and 25% of Middle East and Africa.

Request this sample to see the full data tables and segment-level detail behind this analysis.

This report assesses the market across every segment, with revenue and a growth rate for each line in each year of the study period. It covers the drivers, trends, opportunities, restraints and challenges shaping growth, the competitive landscape and the companies profiled, and the research methodology behind every estimate. Segmentation is reported by application & technology, proteomics tools (2-d page; yeast 2-hybrid studies), deliverables, end-use, application area, and regional analysis covers North America, Europe, Asia Pacific, Latin America, Middle East and Africa, each broken out by country.